B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
ACRS
Aclaris TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.20
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-11
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+45.4
Score
AI commentary
Primary-source tone is constructive but the setup is still monitoring-oriented. The May 7 company filing gave favorable early ATI-052 framing and runway support, but recent external coverage in the packet is thin, no verified analyst revision set is available, and the June 4 filing added no operating news. With sparse buzz and a negative deterministic prior, sentiment should be treated as cautious rather than bullish.
RankAlpha Sentiment Codex - 2026-06-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07eventQ1 update reinforced runway and ATI-052 early profileMedium impact
The May 7 earnings 8-K said Aclaris reported first-quarter 2026 financial results, highlighted positive full Phase 1a SAD/MAD ATI-052 data with potential extended dosing, and said cash runway is expected to support pipeline development through 2028, which reduced near-term financing pressure but did not remove execution risk [#SEC-8K-2026-05-07].
2026-09-30catalystATI-052 Phase 1b asthma and atopic dermatitis topline in 2H 2026High impact
Management said both ongoing placebo-controlled Phase 1b proof-of-concept trials for ATI-052 are expected to produce topline results in the second half of 2026, making this the clearest rerating setup for the shares if the early PK/PD signal translates into patient data [#SEC-8K-2026-05-07].
2026-12-15catalystBosakitug Phase 2 atopic dermatitis readout in Q4 2026High impact
The same May 7 company filing said enrollment is complete in the 109-patient Phase 2 bosakitug trial in atopic dermatitis and that topline results are expected in the fourth quarter of 2026, leaving Aclaris with a second major binary readout later this year [#SEC-8K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology